Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.2 SEK | -2.04% | -5.51% | -54.37% |
Business Summary
Number of employees: 17
Sales per Business
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Cell Therapies
100.0
%
| 6 | 100.0 % | 10 | 100.0 % | +80.96% |
Sales per region
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Sweden
100.0
%
| 6 | 100.0 % | 10 | 100.0 % | +80.96% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Mathias Svahn
CEO | Chief Executive Officer | 48 | 14-03-18 |
Edvard Smith
FOU | Founder | 73 | 14-03-18 |
Patrik Fagerholm
DFI | Director of Finance/CFO | 57 | 21-08-31 |
Chairman | 83 | 13-12-31 | |
Sofia Sisay
CTO | Chief Tech/Sci/R&D Officer | 43 | 21-12-31 |
Lindsay Davies
CTO | Chief Tech/Sci/R&D Officer | 45 | 19-12-31 |
Corporate Officer/Principal | 38 | 17-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 83 | 13-12-31 | |
Founder | 74 | 14-03-18 | |
Edvard Smith
FOU | Founder | 73 | 14-03-18 |
Camilla Sandberg
BRD | Director/Board Member | 57 | 16-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 34,379,523 | 20,679,448 ( 60.15 %) | 0 | 60.15 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
-54.37% | 3.88M | |
+26.37% | 48.16B | |
-1.01% | 41.73B | |
+41.76% | 41.03B | |
-5.31% | 28.77B | |
+9.34% | 25.59B | |
-21.69% | 18.96B | |
+6.23% | 12.92B | |
+26.99% | 12.03B | |
-3.38% | 11.77B |
- Stock Market
- Equities
- NXTCL Stock
- Company NextCell Pharma AB